In a March 3, 2026 press announcement (FDA.gov press announcement, March 3, 2026), the FDA issued warning letters to 30 telehealth companies specifically for making claims that implied sameness with FDA-approved products - a category-wide compliance signal every buyer should understand
Despite this promise, considerable challenges remain particularly the difficulty in delivering drugs across the bloodbrain barrier to selectively activate central GLP-1 neurons
Why compounded formulations are different Brand-name semaglutide products from Novo Nordisk contain proprietary stabilizers, buffers, and preservatives that help the molecule maintain its structure outside the fridge
Some patients notice appetite changes within the first few weeks
GLP-1 Agonist Medications Targeting GLP-1 has become a primary area of focus for cardiometabolic health, including weight management